Novozymes completes merger with Chr. Hansen, new entity named as Novonesis

The combination of Novozymes and Chr. Hansen is now successfully completed, creating Novonesis – a leading global biosolutions partner

0
89
New Delhi: On December 12, 2022, Novozymes and Chr. Hansen entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.
All regulatory approvals and registrations are now in place and the proposed combination is successfully completed following the final registration with the Danish Business Authority.
Novonesis, the combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries.
Ester Baiget, President and CEO of Novonesis, says: “We have successfully combined Novozymes and Chr. Hansen and today we come together as one leading global biosolutions partner. Novonesis combines our joint strengths and the wonders of biology, and we are set to lead a new era of biosolutions. We will innovate and develop transformative biosolutions that improve the way we all produce, consume and live. And we have gathered the brightest minds and together with my 10,000 colleagues, we will unlock the limitless potential of biosolutions.”
Cees de Jong, Chairman of Novonesis, adds: “I am pleased to witness the realization of the Novozymes and Chr. Hansen combination, creating a true global biosolutions leader. We will continue to create powerful biosolutions for our customers and partners based on our more than 100 years of innovation and application expertise. Together, we will serve as a growth partner to our customers; a value creator to our shareholders; and a company that has a significant, positive impact on society and the planet. Novonesis builds on a shared heritage of sustainability leadership and will keep leading the way.”
The combination of Novozymes and Chr. Hansen will create a leading global biosolutions partner with a broad biological toolbox and a diversified portfolio in attractive markets. The combined group will have annual revenue of approximately EUR 3.7 billion with solid profitability and cash generation.
Half of the portfolio will focus on enabling healthier lives and producing better foods. The other half will address reducing chemical use and targeting climate neutral practices.
The combined group will operate a global network of R&D and application centers as well as manufacturing sites and will employ around 10,000 talented and purpose-driven employees who are inspired by the power of biosolutions.
Proposed Board of Directors (excluding employee elected)
  • Cornelis (Cees) de Jong, as Chair (independent)
  • Jesper Brandgaard, as Vice Chair (independent)
  • Heine Dalsgaard (non-independent)
  • Sharon James (independent)
  • Kasim Kutay (non-independent)
  • Lise Kaae (independent)
  • Kevin Lane (independent)
  • Morten Otto Alexander Sommer (independent)
  • Kim Stratton (independent)
As announced on October 10, 2023, the following nine executives have been appointed to the future Executive Leadership Team:
Executive Leadership Team
  • Ester Baiget, CEO
  • Rainer Lehmann, CFO
  • Jacob Paulsen, EVP, Food & Beverage Biosolutions
  • Amy Byrick, EVP, Human Health Biosolutions
  • Tina Sejersgaard Fanø, EVP, Planetary Health Biosolutions
  • Claus Crone Fuglsang, Chief Scientific Officer
  • Anders Lund, Chief Operating Officer
  • Henrik Joerck Nielsen, EVP, Strategy & Integration
  • Morten Enggaard Rasmussen, EVP, People & Stakeholder Relations
  • Winnie Bügel, General Counsel – Legal (temporary role)